Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07396389
Starting soon Not applicable

Understanding How Young Adults Perceive Blurred Image Quality and Creating a Model Predicting Their Quality Ratings

NCT07396389 · tracked via the Priya Life Science France tracker
Sponsor
Essilor International
Phase
Not applicable
Started
2026-02
Last updated
2026-02-11

Condition(s) studied

Healthy Young Adults

Investigational drug(s) / intervention(s)

eye examimage rating

eye exam: participants will follow a complete eye exam

image rating: participants will have to rate the perceived quality of images on a 10 points scale

Study summary

This clinical study wants to understand how blurred images look to young adults.

The main question is: How do different kinds of images and different kinds of blur change the way people think those images look? Participants will get an eye exam, then look at several blurred images and rate how good or bad each one looks on a quality scale from 1 (very bad) to 10 (very good).

Eligibility

Sex
ALL
Min age
18 Years
Max age
30 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Distance refractive error (equivalent sphere) between -7 D and +5 D * Astigmatism below 4D * Minimum corrected visual acuity: 10/10 Exclusion Criteria: * Aphakic or pseudophakic eye surgery * Reported systemic pathology that affects vision * Medical treatment or taking medications that affect vision * Severe ocular pathology declared, involving a loss of visual field as in glaucoma, a loss of acuity * Reported neurological deficit, including a history of seizure or sensorimotor coordination disorders, vestibular or cerebellar pathology * Binocular vision problems such as amblyopia, strabismus, or double vision

Primary outcome measure(s)

  • Subjective image quality rating on a quality scale from 1 (very bad) to 10 (very good) — Day one

Trial sites (1)

FacilityCityRegionStatus
LABORATOIRE LuMIn - ENS Paris-Saclay Gif-sur-Yvette France

More Essilor International trials in France

A Study on Body Posture and Eye Movements During Screen Usage on Adults Aged 18 to 65 Wearing Various Types of Eyeglasses Recruiting
The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit. Recruiting
Visual and Postural Behavior in Myopic and Non-Myopic Teenagers Recruiting
Study on the Effect of Filters on Discomfort Glare on Healthy Adults Starting soon
Essilor® Stellest® Lenses Multicentre European Study (SLOMES) Active, not recruiting

Other trials for the same condition

Effects of Feedback and Aging on Aiming Movements in Virtual Reality Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07396389 on ClinicalTrials.gov ↗ ← All trials in France